Related Experiment Video
Updated: Apr 27, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer
Yutaka Yanagihara1, Nozomu Tanji, Noriyoshi Miura
1Department of Urology, Ehime University Graduate School of Medicine, Toon, Japan.
Background:
To improve the prognosis of patients with urachal cancer and establish an effective chemotherapeutic regimen for distant metastases.
Methods:
We conducted a retrospective study to evaluate the efficacy and safety of a modified combination of 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) therapy in patients with metastatic urachal cancer.
Results:
Five patients were treated with mFOLFOX6. Their median age was 65 years (range 41-80). The median follow-up time was 42 months (range 18-46). Two of the 5 patients (40%) showed an objective response: 1 achieved a clinically complete response and 1 a partial response. The grade 3/4 toxicity associated with this regimen was primarily neutropenia, but febrile neutropenia was not observed. Oxaliplatin treatment was discontinued because of a grade 2 allergic reaction in 1 patient. Grade 2 peripheral sensory neuropathy caused by oxaliplatin was observed in 2 patients, and the OPTIMOX (stop and go) approach had to be adopted.
Conclusions:
mFOLFOX6 appears to be effective for the treatment of metastatic urachal cancer.
Related Concept Videos
Urinary Tract Calculi VI: Surgical Management
Treatment Resistant Cancers
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Urinary Tract Calculi III: Medical Management

